Literature DB >> 35325815

Phases of volume loss in patients with known frontotemporal lobar degeneration spectrum pathology.

Sarah E Burke1, Jeffrey S Phillips2, Christopher A Olm3, Claire S Peterson4, Phillip A Cook5, James C Gee5, Edward B Lee6, John Q Trojanowski6, Lauren Massimo2, David J Irwin4, Murray Grossman2.   

Abstract

Frontotemporal lobar degeneration (FTLD) includes clinically similar FTLD-tau or FTLD-TDP proteinopathies which lack in vivo markers for accurate antemortem diagnosis. To identify early distinguishing sites of cortical atrophy between groups, we retrospectively analyzed in vivo volumetric MRI from 42 FTLD-Tau and 21 FTLD-TDP patients and validated these findings with postmortem measures of pathological burden. Our frequency-based staging model revealed distinct loci of maximal early cortical atrophy in each group, including dorsolateral and medial frontal regions in FTLD-Tau and ventral frontal and anterior temporal regions in FTLD-TDP. Sørenson-Dice calculations between proteinopathy groups showed little overlap of phases. Conversely, within-group subtypes showed good overlap between 3R- and 4R-tauopathies, and between TDP-43 Types A and C for early regions with subtle divergence between subtypes in subsequent phases of atrophy. Postmortem validation found an association of imaging phases with pathologic burden within FTLD-tau (F(4, 238) = 17.44, p < 0.001) and FTLD-TDP (F(4,245) = 42.32, p < 0.001). These results suggest that relatively early, distinct markers of atrophy may distinguish FTLD proteinopathies during life.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Frontotemporal lobar degeneration; Magnetic resonance imaging; Percent area occupied; Sporadic; TDP-43; Tau

Mesh:

Substances:

Year:  2022        PMID: 35325815      PMCID: PMC9241163          DOI: 10.1016/j.neurobiolaging.2022.02.007

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   5.133


  64 in total

1.  Does corticobasal degeneration exist? A clinicopathological re-evaluation.

Authors:  Helen Ling; Sean S O'Sullivan; Janice L Holton; Tamas Revesz; Luke A Massey; David R Williams; Dominic C Paviour; Andrew J Lees
Journal:  Brain       Date:  2010-07       Impact factor: 13.501

2.  Clinical and genetic analyses of familial and sporadic frontotemporal dementia patients in Southern Italy.

Authors:  Rosa Capozzo; Celeste Sassi; Monia B Hammer; Simona Arcuti; Chiara Zecca; Maria R Barulli; Rosanna Tortelli; J Raphael Gibbs; Cynthia Crews; Davide Seripa; Francesco Carnicella; Claudia Dell'Aquila; Marco Rossi; Filippo Tamma; Francesco Valluzzi; Bruno Brancasi; Francesco Panza; Andrew B Singleton; Giancarlo Logroscino
Journal:  Alzheimers Dement       Date:  2017-03-03       Impact factor: 21.566

3.  Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD).

Authors:  Johannes Brettschneider; Kelly Del Tredici; David J Irwin; Murray Grossman; John L Robinson; Jon B Toledo; Lubin Fang; Vivianna M Van Deerlin; Albert C Ludolph; Virginia M-Y Lee; Heiko Braak; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2014-01-10       Impact factor: 17.088

4.  Random-effects models for longitudinal data.

Authors:  N M Laird; J H Ware
Journal:  Biometrics       Date:  1982-12       Impact factor: 2.571

5.  Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine.

Authors:  David J Irwin; Nigel J Cairns; Murray Grossman; Corey T McMillan; Edward B Lee; Vivianna M Van Deerlin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2014-12-31       Impact factor: 17.088

6.  Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia.

Authors:  William W Seeley; Richard Crawford; Katya Rascovsky; Joel H Kramer; Michael Weiner; Bruce L Miller; Maria Luisa Gorno-Tempini
Journal:  Arch Neurol       Date:  2008-02

7.  Deep clinical and neuropathological phenotyping of Pick disease.

Authors:  David J Irwin; Johannes Brettschneider; Corey T McMillan; Felicia Cooper; Christopher Olm; Steven E Arnold; Vivianna M Van Deerlin; William W Seeley; Bruce L Miller; Edward B Lee; Virginia M-Y Lee; Murray Grossman; John Q Trojanowski
Journal:  Ann Neurol       Date:  2015-12-25       Impact factor: 10.422

8.  A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank.

Authors:  Jon B Toledo; Vivianna M Van Deerlin; Edward B Lee; EunRan Suh; Young Baek; John L Robinson; Sharon X Xie; Jennifer McBride; Elisabeth M Wood; Theresa Schuck; David J Irwin; Rachel G Gross; Howard Hurtig; Leo McCluskey; Lauren Elman; Jason Karlawish; Gerard Schellenberg; Alice Chen-Plotkin; David Wolk; Murray Grossman; Steven E Arnold; Leslie M Shaw; Virginia M-Y Lee; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2013-08-24       Impact factor: 21.566

9.  Mapping the structural core of human cerebral cortex.

Authors:  Patric Hagmann; Leila Cammoun; Xavier Gigandet; Reto Meuli; Christopher J Honey; Van J Wedeen; Olaf Sporns
Journal:  PLoS Biol       Date:  2008-07-01       Impact factor: 8.029

10.  Screening for cognition and behaviour changes in ALS.

Authors:  Sharon Abrahams; Judith Newton; Elaine Niven; Jennifer Foley; Thomas H Bak
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2013-06-19       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.